Wockhardt Ltd to exit U.S. generics business to reallocate capital toward high-impact growth areas.
"Wockhardt is undertaking significant strategic realignment of its US business in line with its long-term vision to build a differentiated, innovation-driven pharmaceutical enterprise. As part of this transition, the Company has taken decision to exit the US generic pharmaceutical segment, paving the way for deeper focus and investment in its advanced product portfolio," said the company in a stock exchange filing.
Comments
Post a Comment